Anthony Melendez

Anthony Melendez, MD, currently serves as the Director at Braidwell since May 2022 and as a Board Observer at Gennao Bio since 2023. Prior to these roles, Melendez held multiple positions at AbbVie from September 2019 to May 2022, including Director of AbbVie Ventures and Director of Corporate Strategy. Melendez has also contributed as a Board Observer for several companies, including Trishula Therapeutics, Magnolia Neurosciences, PACT Pharma, ESCAPE Bio, Nitrase Therapeutics, and Quanta Therapeutics during 2021-2022. Previously, Melendez worked in Biotech Equity Research at Cowen Inc. from 2018 to 2019, focusing on Hematology, Oncology, Gene Therapy, and Immunology. Melendez holds an MBA from Harvard Business School, an MD from the Icahn School of Medicine at Mount Sinai, and a BA from the University of Florida.